Cancer research

publication venue for

Editor's Note: PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR. 2025
Editor's Note: Androgen-Induced Differentiation and Tumorigenicity of Human Prostate Epithelial Cells. 2024
Correction: ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer. 2023
Correction: Enhanced Lipid Accumulation and Metabolism Are Required for the Differentiation and Activation of Tumor-Associated Macrophages. 2022
Correction: p62/SQSTM1 Cooperates with Hyperactive mTORC1 to Regulate Glutathione Production, Maintain Mitochondrial Integrity, and Promote Tumorigenesis. 2020
Gastrin-releasing peptide-related peptides in a human malignant lung carcinoid tumor. 1983
In vivo and in vitro biological activities of two human cell lines derived from anaplastic lung cancers. 1983
A MERTK-Targeting Antibody-Drug Conjugate Selectively Depletes M2 Tumor-Associated Macrophages and MERTK-Expressing Cancer Cells. 2026
A Double-Negative Prostate Cancer Subtype is Vulnerable to SWI/SNF-Targeting Degrader Molecules. 2026
Deep-Learning Tool ScVital Enables Species-Agnostic Integration of Cancer Cell States. 2025
Epigenetic De-repression of PROX1 Promotes Neuroendocrine Prostate Cancer Progression. 2025
Kinome-Focused CRISPR-Cas9 Screens in African Ancestry Patient-Derived Breast Cancer Organoids Identify Essential Kinases and Synergy of EGFR and FGFR1 Inhibition.. 85. 2025
ASCL1 Drives the Development of Neuroendocrine Prostate Cancer.. 84. 2024
Scribble Deficiency Promotes Pancreatic Ductal Adenocarcinoma Development and Metastasis.. 84. 2024
Increased Protein Kinase A Activity Induces Fibrolamellar Hepatocellular Carcinoma Features Independent of DNAJB1.. 84. 2024
A Genomics-Driven Artificial Intelligence-Based Model Classifies Breast Invasive Lobular Carcinoma and Discovers CDH1 Inactivating Mechanisms. 2024
Hypoxic Memory Mediates Prolonged Tumor Intrinsic Type I Interferon Suppression to Promote Breast Cancer Progression. 2024
Obesogenic High-Fat Diet and MYC Cooperate to Promote Lactate Accumulation and Tumor Microenvironment Remodeling in Prostate Cancer.. 84. 2024
Cancer Cells Hijack Physiologic Metabolic Signals to Seed Liver Metastasis.. 84. 2024
How Artificial Intelligence Unravels the Complex Web of Cancer Drug Response. 2024
Adipose Triglyceride Lipase Is a Therapeutic Target in Advanced Prostate Cancer That Promotes Metabolic Plasticity.. 84. 2024
Decoding Serine Metabolism: Unveiling Novel Pathways for Evolving Cancer Therapies. 2024
XPO1 Enables Adaptive Regulation of mRNA Export Required for Genotoxic Stress Tolerance in Cancer Cells.. 84. 2024
Oncogenic Transformation Drives DNA Methylation Loss and Transcriptional Activation at Transposable Element Loci.. 83. 2023
Hypoxia Potentiates the Inflammatory Fibroblast Phenotype Promoted by Pancreatic Cancer Cell-Derived Cytokines.. 83. 2023
Microenvironment-Driven Dynamic Chromatin Changes in Glioblastoma Recapitulate Early Neural Development at Single-Cell Resolution.. 83. 2023
CellMinerCDB: NCATS is a Web-Based Portal Integrating Public Cancer Cell Line Databases for Pharmacogenomic Explorations. 2023
KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer.. 83. 2023
Mitochondrial DNA Mutations as Natural Barcodes for Lineage Tracing of Murine Tumor Models.. 83. 2023
Systematic Interrogation of Tumor Cell Resistance to Chimeric Antigen Receptor T-cell Therapy in Pancreatic Cancer.. 83. 2023
A Pro-Regenerative Environment Triggers Premalignant to Malignant Transformation of Senescent Hepatocytes.. 83. 2023
The cytidine deaminase APOBEC3G contributes to cancer mutagenesis and clonal evolution in bladder cancer. 2022
Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis.. 82. 2022
GLS2 Is a Tumor Suppressor and a Regulator of Ferroptosis in Hepatocellular Carcinoma.. 82. 2022
CHD1 Promotes Sensitivity to Aurora Kinase Inhibitors by Suppressing Interaction of AURKA with Its Coactivator TPX2.. 82. 2022
Gain of Chromosome 1q Perturbs a Competitive Endogenous RNA Network to Promote Melanoma Metastasis.. 82. 2022
The prostate cancer androgen receptor cistrome in African American men associates with upregulation of lipid metabolism and immune response. 2022
The Oncogenic PI3K-Induced Transcriptomic Landscape Reveals Key Functions in Splicing and Gene Expression Regulation.. 82. 2022
Immune Determinants of the Association between Tumor Mutational Burden and Immunotherapy Response across Cancer Types.. 82. 2022
Pyruvate kinase M1 suppresses development and progression of prostate adenocarcinoma. 2022
Colorectal cancer develops inherent radiosensitivity that can be predicted using patient-derived organoids. 2022
Understanding Drug Sensitivity and Tackling Resistance in Cancer.. 82. 2022
A Urinary Drug-Disposing Approach as an Alternative to Intravesical Chemotherapy for Treating Nonmuscle Invasive Bladder Cancer.. 82. 2022
Hotspot ESR1 Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis.. 82. 2022
CIC-Mediated Modulation of MAPK Signaling Opposes Receptor Tyrosine Kinase Inhibitor Response in Kinase-Addicted Sarcoma.. 82. 2022
Inhibition of XPO1 Sensitizes Small Cell Lung Cancer to First- and Second-Line Chemotherapy.. 82. 2021
Activation of Notch and Myc Signaling via B-cell-Restricted Depletion of Dnmt3a Generates a Consistent Murine Model of Chronic Lymphocytic Leukemia.. 81. 2021
Myeloid-Derived Suppressive Cell Expansion Promotes Melanoma Growth and Autoimmunity by Inhibiting CD40/IL27 Regulation in Macrophages.. 81. 2021
Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell Lymphomas.. 81. 2021
RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer.. 81. 2021
Quantitative In Vivo Analyses Reveal a Complex Pharmacogenomic Landscape in Lung Adenocarcinoma.. 81. 2021
The CD200-CD200R Axis Promotes Squamous Cell Carcinoma Metastasis via Regulation of Cathepsin K.. 81. 2021
Diabetes Risk Reduction Diet and Survival after Breast Cancer Diagnosis.. 81. 2021
Locus-Specific Characterization of Human Endogenous Retrovirus Expression in Prostate, Breast, and Colon Cancers.. 81. 2021
Genomic Alterations in PIK3CA-Mutated Breast Cancer Result in mTORC1 Activation and Limit the Sensitivity to PI3Kα Inhibitors.. 81. 2021
Activated ALK Cooperates with N-Myc via Wnt/β-Catenin Signaling to Induce Neuroendocrine Prostate Cancer.. 81. 2021
Cancer-Associated Fibroblasts Promote Aggressive Gastric Cancer Phenotypes via Heat Shock Factor 1-Mediated Secretion of Extracellular Vesicles.. 81. 2021
ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer.. 81. 2021
Exogenous and Endogenous Sources of Serine Contribute to Colon Cancer Metabolism, Growth, and Resistance to 5-Fluorouracil.. 81. 2021
Induction of ADAM10 by Radiation Therapy Drives Fibrosis, Resistance, and Epithelial-to-Mesenchyal Transition in Pancreatic Cancer.. 81. 2021
Therapy-Induced Transdifferentiation Promotes Glioma Growth Independent of EGFR Signaling.. 81. 2021
Newly Identified Members of FGFR1 Splice Variants Engage in Cross-talk with AXL/AKT Axis in Salivary Adenoid Cystic Carcinoma.. 81. 2021
Identifying Clear Cell Renal Cell Carcinoma Coexpression Networks Associated with Opioid Signaling and Survival.. 81. 2020
Postdiagnostic Fruit and Vegetable Consumption and Breast Cancer Survival: Prospective Analyses in the Nurses' Health Studies.. 80. 2020
Evolution of the Epigenetic Landscape in Childhood B Acute Lymphoblastic Leukemia and Its Role in Drug Resistance.. 80. 2020
Pleiotropic Mechanisms Drive Endocrine Resistance in the Three-Dimensional Bone Microenvironment.. 81. 2020
Nitrogen Trapping as a Therapeutic Strategy in Tumors with Mitochondrial Dysfunction.. 80. 2020
FBXW7 Triggers Degradation of KMT2D to Favor Growth of Diffuse Large B-cell Lymphoma Cells.. 80. 2020
Heritability of Mammographic Breast Density, Density Change, Microcalcifications, and Masses.. 80. 2020
Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma.. 80. 2020
iNOS Regulates the Therapeutic Response of Pancreatic Cancer Cells to Radiotherapy.. 80. 2020
Enhanced Lipid Accumulation and Metabolism Are Required for the Differentiation and Activation of Tumor-Associated Macrophages.. 80. 2020
Oncogenic ERG Represses PI3K Signaling through Downregulation of IRS2.. 80. 2020
A Prospective Analysis of Circulating Plasma Metabolites Associated with Ovarian Cancer Risk.. 80. 2020
Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer.. 80. 2019
Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma.. 79. 2019
Integrative Genomic Characterization Identifies Molecular Subtypes of Lung Carcinoids.. 79. 2019
Inflammatory Breast Cancer Promotes Development of M2 Tumor-Associated Macrophages and Cancer Mesenchymal Cells through a Complex Chemokine Network.. 79. 2019
Inhibition of EphB4-Ephrin-B2 Signaling Reprograms the Tumor Immune Microenvironment in Head and Neck Cancers.. 79. 2019
Targeted Metabolomics Identifies the Cytochrome P450 Monooxygenase Eicosanoid Pathway as a Novel Therapeutic Target of Colon Tumorigenesis.. 79. 2019
MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors.. 79. 2019
The Transcriptional Regulator Sin3A Contributes to the Oncogenic Potential of STAT3.. 79. 2019
Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions.. 79. 2019
Tumor-Associated Macrophages Enhance Tumor Hypoxia and Aerobic Glycolysis.. 79. 2019
Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.. 79. 2018
Hyperpolarized MRI Visualizes Warburg Effects and Predicts Treatment Response to mTOR Inhibitors in Patient-Derived ccRCC Xenograft Models.. 79. 2018
Retraction: Inactivation of the Quinone Oxidoreductases NQO1 and NQO2 Strongly Elevates the Incidence and Multiplicity of Chemically Induced Skin Tumors.. 78. 2018
A Novel Germline Variant in CSF3R Reduces N-Glycosylation and Exerts Potent Oncogenic Effects in Leukemia.. 78. 2018
Reduced CD160 Expression Contributes to Impaired NK-cell Function and Poor Clinical Outcomes in Patients with HCC.. 78. 2018
Pooled Analysis of Nine Cohorts Reveals Breast Cancer Risk Factors by Tumor Molecular Subtype.. 78. 2018
IL1 Receptor Antagonist Controls Transcriptional Signature of Inflammation in Patients with Metastatic Breast Cancer.. 78. 2018
Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations.. 78. 2018
The Canonical Wnt Pathway Drives Macropinocytosis in Cancer.. 78. 2018
Metabolic Imaging of the Human Brain with Hyperpolarized ¹³C Pyruvate Demonstrates ¹³C Lactate Production in Brain Tumor Patients.. 78. 2018
Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers.. 78. 2018
Novel Richter Syndrome Xenograft Models to Study Genetic Architecture, Biology, and Therapy Responses.. 78. 2018
Targeting Brain-Adaptive Cancer Stem Cells Prohibits Brain Metastatic Colonization of Triple-Negative Breast Cancer.. 78. 2018
Germline Lysine-Specific Demethylase 1 (LSD1/KDM1A) Mutations Confer Susceptibility to Multiple Myeloma.. 78. 2018
Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize.. 78. 2018
Fc-Mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models.. 78. 2018
CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion.. 78. 2018
Utility of Single-Cell Genomics in Diagnostic Evaluation of Prostate Cancer.. 78. 2017
YAP1 and COX2 Coordinately Regulate Urothelial Cancer Stem-like Cells.. 78. 2017
PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models.. 77. 2017
Rapid Intraoperative Diagnosis of Pediatric Brain Tumors Using Stimulated Raman Histology.. 78. 2017
An Akt3 Splice Variant Lacking the Serine 472 Phosphorylation Site Promotes Apoptosis and Suppresses Mammary Tumorigenesis.. 78. 2017
MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia.. 77. 2017
Inflammatory Monocytes Promote Perineural Invasion via CCL2-Mediated Recruitment and Cathepsin B Expression.. 77. 2017
Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition.. 77. 2017
PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4⁺ TILs in the Presence of PD-L1⁺ TAMs.. 77. 2017
Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer.. 77. 2017
Therapeutic Effects of XPO1 Inhibition in Thymic Epithelial Tumors.. 77. 2017
S100A4 Is a Biomarker and Regulator of Glioma Stem Cells That Is Critical for Mesenchymal Transition in Glioblastoma.. 77. 2017
Transglutaminase 2 Inhibition Reverses Mesenchymal Transdifferentiation of Glioma Stem Cells by Regulating C/EBPβ Signaling.. 77. 2017
A Naturally Generated Decoy of the Prostate Apoptosis Response-4 Protein Overcomes Therapy Resistance in Tumors.. 77. 2017
ETV1-Positive Cells Give Rise to BRAF^V600E -Mutant Gastrointestinal Stromal Tumors.. 77. 2017
p62/SQSTM1 Cooperates with Hyperactive mTORC1 to Regulate Glutathione Production, Maintain Mitochondrial Integrity, and Promote Tumorigenesis.. 77. 2017
Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer.. 77. 2017
SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.. 77. 2017
Targeting Autocrine CCL5-CCR5 Axis Reprograms Immunosuppressive Myeloid Cells and Reinvigorates Antitumor Immunity.. 77. 2017
Multinuclear NMR and MRI Reveal an Early Metabolic Response to mTOR Inhibition in Sarcoma.. 77. 2017
PanIN Neuroendocrine Cells Promote Tumorigenesis via Neuronal Cross-talk.. 77. 2017
Combination Therapy Targeting BCL6 and Phospho-STAT3 Defeats Intratumor Heterogeneity in a Subset of Non-Small Cell Lung Cancers.. 77. 2017
E3 Ubiquitin Ligase UBR5 Drives the Growth and Metastasis of Triple-Negative Breast Cancer.. 77. 2017
Distinct Levels of Radioresistance in Lgr5⁺ Colonic Epithelial Stem Cells versus Lgr5⁺ Small Intestinal Stem Cells.. 77. 2017
Evolution of Cancer Stem-like Cells in Endocrine-Resistant Metastatic Breast Cancers Is Mediated by Stromal Microvesicles.. 77. 2017
Effective Combination Therapies for B-cell Lymphoma Predicted by a Virtual Disease Model.. 77. 2017
Biomarker-Based PET Imaging of Diffuse Intrinsic Pontine Glioma in Mouse Models.. 77. 2017
ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer.. 77. 2017
RB Loss Promotes Prostate Cancer Metastasis.. 77. 2016
Basophils Promote Tumor Rejection via Chemotaxis and Infiltration of CD8+ T Cells.. 77. 2016
IDH2 Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity.. 76. 2016
Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy.. 76. 2016
miR-1298 Inhibits Mutant KRAS-Driven Tumor Growth by Repressing FAK and LAMB3.. 76. 2016
Deep Sequencing Reveals a Novel miR-22 Regulatory Network with Therapeutic Potential in Rhabdomyosarcoma.. 76. 2016
Plasma 25-Hydroxyvitamin D and Risk of Breast Cancer in Women Followed over 20 Years.. 76. 2016
SIRT2 Deacetylates and Inhibits the Peroxidase Activity of Peroxiredoxin-1 to Sensitize Breast Cancer Cells to Oxidant Stress-Inducing Agents.. 76. 2016
Exercise and Prognosis on the Basis of Clinicopathologic and Molecular Features in Early-Stage Breast Cancer: The LACE and Pathways Studies.. 76. 2016
Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia.. 76. 2016
Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors.. 76. 2016
Tumor Cell Invasion Can Be Blocked by Modulators of Collagen Fibril Alignment That Control Assembly of the Extracellular Matrix.. 76. 2016
mTORC1-Driven Tumor Cells Are Highly Sensitive to Therapeutic Targeting by Antagonists of Oxidative Stress.. 76. 2016
Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations.. 76. 2016
NOTCH Signaling Regulates Asymmetric Cell Fate of Fast- and Slow-Cycling Colon Cancer-Initiating Cells.. 76. 2016
PTP1B Deficiency Enables the Ability of a High-Fat Diet to Drive the Invasive Character of PTEN-Deficient Prostate Cancers.. 76. 2016
CK2α' Drives Lung Cancer Metastasis by Targeting BRMS1 Nuclear Export and Degradation.. 76. 2016
The Proliferative Activity of Mammary Epithelial Cells in Normal Tissue Predicts Breast Cancer Risk in Premenopausal Women.. 76. 2016
Cyclin A1 and P450 Aromatase Promote Metastatic Homing and Growth of Stem-like Prostate Cancer Cells in the Bone Marrow.. 76. 2016
In Vivo Visualization and Characterization of Epithelial-Mesenchymal Transition in Breast Tumors.. 76. 2016
Combined Treatment with Epigenetic, Differentiating, and Chemotherapeutic Agents Cooperatively Targets Tumor-Initiating Cells in Triple-Negative Breast Cancer.. 76. 2016
Characterization of a c-Rel Inhibitor That Mediates Anticancer Properties in Hematologic Malignancies by Blocking NF-κB-Controlled Oxidative Stress Responses.. 76. 2016
EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer.. 76. 2016
Interactions between Adipocytes and Breast Cancer Cells Stimulate Cytokine Production and Drive Src/Sox2/miR-302b-Mediated Malignant Progression.. 76. 2016
Activation of Hematopoietic Stem/Progenitor Cells Promotes Immunosuppression Within the Pre-metastatic Niche.. 76. 2015
VEGF-A/VEGFR Inhibition Restores Hematopoietic Homeostasis in the Bone Marrow and Attenuates Tumor Growth.. 76. 2015
Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation.. 75. 2015
Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53.. 75. 2015
STAT3 Blockade Inhibits Radiation-Induced Malignant Progression in Glioma.. 75. 2015
Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma.. 75. 2015
Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized Immunotherapy.. 75. 2015
Grade-Dependent Metabolic Reprogramming in Kidney Cancer Revealed by Combined Proteomics and Metabolomics Analysis.. 75. 2015
High-Frequency Targetable EGFR Mutations in Sinonasal Squamous Cell Carcinomas Arising from Inverted Sinonasal Papilloma.. 75. 2015
Novel Associations between Common Breast Cancer Susceptibility Variants and Risk-Predicting Mammographic Density Measures.. 75. 2015
TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity.. 75. 2015
Development of Resistance to EGFR-Targeted Therapy in Malignant Glioma Can Occur through EGFR-Dependent and -Independent Mechanisms.. 75. 2015
Coordinate loss of MAP3K7 and CHD1 promotes aggressive prostate cancer.. 75. 2015
CDK4/6 Inhibitor PD 0332991 Sensitizes Acute Myeloid Leukemia to Cytarabine-Mediated Cytotoxicity.. 75. 2015
Notch suppresses angiogenesis and progression of hepatic metastases.. 75. 2015
CLK2 Is an Oncogenic Kinase and Splicing Regulator in Breast Cancer.. 75. 2015
ERBB3-independent activation of the PI3K pathway in EGFR-mutant lung adenocarcinomas.. 75. 2015
CCR5 receptor antagonists block metastasis to bone of v-Src oncogene-transformed metastatic prostate cancer cell lines.. 74. 2014
Activin upregulation by NF-κB is required to maintain mesenchymal features of cancer stem-like cells in non-small cell lung cancer.. 75. 2014
Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics.. 75. 2014
AKT1 and MYC induce distinctive metabolic fingerprints in human prostate cancer.. 74. 2014
Astrocyte elevated gene-1 interacts with Akt isoform 2 to control glioma growth, survival, and pathogenesis.. 74. 2014
Densely ionizing radiation acts via the microenvironment to promote aggressive Trp53-null mammary carcinomas.. 74. 2014
Activated d16HER2 homodimers and SRC kinase mediate optimal efficacy for trastuzumab.. 74. 2014
Epigenetic states of cells of origin and tumor evolution drive tumor-initiating cell phenotype and tumor heterogeneity.. 74. 2014
NACK is an integral component of the Notch transcriptional activation complex and is critical for development and tumorigenesis.. 74. 2014
Pyrvinium attenuates Hedgehog signaling downstream of smoothened.. 74. 2014
Slug promotes survival during metastasis through suppression of Puma-mediated apoptosis.. 74. 2014
Rapamycin rescues ABT-737 efficacy in small cell lung cancer.. 74. 2014
Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia.. 74. 2014
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.. 74. 2014
Androgen receptor splice variants determine taxane sensitivity in prostate cancer.. 74. 2014
Suppression of microRNA-9 by mutant EGFR signaling upregulates FOXP1 to enhance glioblastoma tumorigenicity.. 74. 2014
The transcriptional regulatory network of proneural glioma determines the genetic alterations selected during tumor progression.. 74. 2014
Oligodendrocyte progenitor cells promote neovascularization in glioma by disrupting the blood-brain barrier.. 74. 2013
High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development.. 74. 2013
Risk of ovarian cancer and the NF-κB pathway: genetic association with IL1A and TNFSF10.. 74. 2013
Prodigiosin rescues deficient p53 signaling and antitumor effects via upregulating p73 and disrupting its interaction with mutant p53.. 74. 2013
Activation of the FGFR-STAT3 pathway in breast cancer cells induces a hyaluronan-rich microenvironment that licenses tumor formation.. 74. 2013
Lenalidomide inhibits lymphangiogenesis in preclinical models of mantle cell lymphoma.. 73. 2013
Novel modeling of cancer cell signaling pathways enables systematic drug repositioning for distinct breast cancer metastases.. 73. 2013
Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization.. 73. 2013
Gleason grade progression is uncommon.. 73. 2013
Double minute chromosomes in glioblastoma multiforme are revealed by precise reconstruction of oncogenic amplicons.. 73. 2013
Notch1-induced brain tumor models the sonic hedgehog subgroup of human medulloblastoma.. 73. 2013
PPARδ induces estrogen receptor-positive mammary neoplasia through an inflammatory and metabolic phenotype linked to mTOR activation.. 73. 2013
PLZF confers effector functions to donor T cells that preserve graft-versus-tumor effects while attenuating GVHD.. 73. 2013
Vitronectin-αvβ3 integrin engagement directs hypoxia-resistant mTOR activity and sustained protein synthesis linked to invasion by breast cancer cells.. 73. 2013
Avirulent Toxoplasma gondii generates therapeutic antitumor immunity by reversing immunosuppression in the ovarian cancer microenvironment.. 73. 2013
Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism.. 73. 2013
Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity.. 73. 2013
Enhanced effector responses in activated CD8+ T cells deficient in diacylglycerol kinases.. 73. 2013
Activation of HIF2α in kidney proximal tubule cells causes abnormal glycogen deposition but not tumorigenesis.. 73. 2013
Spreaders and sponges define metastasis in lung cancer: a Markov chain Monte Carlo mathematical model.. 73. 2013
TNRC9 downregulates BRCA1 expression and promotes breast cancer aggressiveness.. 73. 2013
Oncogenic activation of Pak1-dependent pathway of macropinocytosis determines BCG entry into bladder cancer cells.. 73. 2013
BRMS1 suppresses lung cancer metastases through an E3 ligase function on histone acetyltransferase p300.. 73. 2012
STC1 expression by cancer-associated fibroblasts drives metastasis of colorectal cancer.. 73. 2012
Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression.. 73. 2012
Hyperpolarized 13C-pyruvate magnetic resonance reveals rapid lactate export in metastatic renal cell carcinomas.. 73. 2012
Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms.. 73. 2012
p38 MAPK in myeloma cells regulates osteoclast and osteoblast activity and induces bone destruction.. 72. 2012
Gliomagenesis arising from Pten- and Ink4a/Arf-deficient neural progenitor cells is mediated by the p53-Fbxw7/Cdc4 pathway, which controls c-Myc.. 72. 2012
Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors.. 72. 2012
Endoneurial macrophages induce perineural invasion of pancreatic cancer cells by secretion of GDNF and activation of RET tyrosine kinase receptor.. 72. 2012
Candidate pathways for promoting differentiation or quiescence of oligodendrocyte progenitor-like cells in glioma.. 72. 2012
MicroRNAs regulate tumor angiogenesis modulated by endothelial progenitor cells.. 73. 2012
PDGF receptor alpha is an alternative mediator of rapamycin-induced Akt activation: implications for combination targeted therapy of synovial sarcoma.. 72. 2012
Resistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-β.. 72. 2012
Common variation at BARD1 results in the expression of an oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity.. 72. 2012
Retinoic acid/alpha-interferon combination inhibits growth and promotes apoptosis in mantle cell lymphoma through Akt-dependent modulation of critical targets.. 72. 2012
Reprogramming tumor-associated dendritic cells in vivo using miRNA mimetics triggers protective immunity against ovarian cancer.. 72. 2012
Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition.. 72. 2012
ARN-509: a novel antiandrogen for prostate cancer treatment.. 72. 2012
Mammographic breast density and breast cancer: evidence of a shared genetic basis.. 72. 2012
Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment.. 72. 2011
A pharmacologic inhibitor of the protease Taspase1 effectively inhibits breast and brain tumor growth.. 72. 2011
A novel method of transcriptional response analysis to facilitate drug repositioning for cancer therapy.. 72. 2011
Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy.. 72. 2011
Genome-wide high-density SNP linkage search for glioma susceptibility loci: results from the Gliogene Consortium.. 71. 2011
Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies.. 71. 2011
Dishevelled 2 signaling promotes self-renewal and tumorigenicity in human gliomas.. 71. 2011
Metabolomic profiling reveals potential markers and bioprocesses altered in bladder cancer progression.. 71. 2011
Generation of a mouse model of Von Hippel-Lindau kidney disease leading to renal cancers by expression of a constitutively active mutant of HIF1α.. 71. 2011
Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer.. 71. 2011
Tissue factor-activated coagulation cascade in the tumor microenvironment is critical for tumor progression and an effective target for therapy.. 71. 2011
Loss of transcription factor KLF5 in the context of p53 ablation drives invasive progression of human squamous cell cancer.. 71. 2011
Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer.. 71. 2011
A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.. 71. 2011
Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation.. 71. 2011
Small RNA sequencing and functional characterization reveals MicroRNA-143 tumor suppressor activity in liposarcoma.. 71. 2011
18F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers.. 71. 2011
Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myeloma.. 71. 2011
An EGFR-ERK-SOX9 signaling cascade links urothelial development and regeneration to cancer.. 71. 2011
Differentiation of NUT midline carcinoma by epigenomic reprogramming.. 71. 2011
Differential expression of S6K2 dictates tissue-specific requirement for S6K1 in mediating aberrant mTORC1 signaling and tumorigenesis.. 71. 2011
CREB is a novel nuclear target of PTEN phosphatase.. 71. 2011
Integrative genomics identifies molecular alterations that challenge the linear model of melanoma progression.. 71. 2011
Expression profiling of liposarcoma yields a multigene predictor of patient outcome and identifies genes that contribute to liposarcomagenesis.. 71. 2011
Modulation of cystatin A expression in human airway epithelium related to genotype, smoking, COPD, and lung cancer.. 71. 2011
Hydrophilic agarose macrobead cultures select for outgrowth of carcinoma cell populations that can restrict tumor growth.. 71. 2011
Three-dimensional culture of mouse renal carcinoma cells in agarose macrobeads selects for a subpopulation of cells with cancer stem cell or cancer progenitor properties.. 71. 2011
Pemetrexed indirectly activates the metabolic kinase AMPK in human carcinomas.. 70. 2010
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction.. 70. 2010
Sphingosine-1-phosphate activates the AKT pathway to protect small intestines from radiation-induced endothelial apoptosis.. 70. 2010
Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors.. 70. 2010
MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma.. 70. 2010
Genomic deregulation during metastasis of renal cell carcinoma implements a myofibroblast-like program of gene expression.. 70. 2010
Impact of stromal sensitivity on radiation response of tumors implanted in SCID hosts revisited.. 70. 2010
Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death.. 70. 2010
Tumor-reactive CD8+ early effector T cells identified at tumor site in primary and metastatic melanoma.. 70. 2010
High levels of Hsp90 cochaperone p23 promote tumor progression and poor prognosis in breast cancer by increasing lymph node metastases and drug resistance.. 70. 2010
Image-based chemical screening identifies drug efflux inhibitors in lung cancer cells.. 70. 2010
Using the transcription factor inhibitor of DNA binding 1 to selectively target endothelial progenitor cells offers novel strategies to inhibit tumor angiogenesis and growth.. 70. 2010
ZIC1 overexpression is oncogenic in liposarcoma.. 70. 2010
PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.. 70. 2010
DNMT3B7, a truncated DNMT3B isoform expressed in human tumors, disrupts embryonic development and accelerates lymphomagenesis.. 70. 2010
Genomic and biological characterization of exon 4 KRAS mutations in human cancer.. 70. 2010
Taspase1 functions as a non-oncogene addiction protease that coordinates cancer cell proliferation and apoptosis.. 70. 2010
Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma.. 70. 2010
Immunohistochemical expression of BRCA1 and lethal prostate cancer.. 70. 2010
Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer.. 70. 2010
Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib.. 70. 2010
Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244).. 70. 2010
Activation of Hedgehog signaling by the environmental toxicant arsenic may contribute to the etiology of arsenic-induced tumors.. 70. 2010
Inactivation of junctional adhesion molecule-A enhances antitumoral immune response by promoting dendritic cell and T lymphocyte infiltration.. 70. 2010
NOTCH signaling is required for formation and self-renewal of tumor-initiating cells and for repression of secretory cell differentiation in colon cancer.. 70. 2010
A microRNA expression signature for cervical cancer prognosis.. 70. 2010
Inactivation of the quinone oxidoreductases NQO1 and NQO2 strongly elevates the incidence and multiplicity of chemically induced skin tumors.. 70. 2010
SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation.. 70. 2010
ZNF238 is expressed in postmitotic brain cells and inhibits brain tumor growth.. 70. 2010
Regulation of ceramide synthase-mediated crypt epithelium apoptosis by DNA damage repair enzymes.. 70. 2010
Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.. 70. 2010
Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.. 70. 2010
Circulating carotenoids, mammographic density, and subsequent risk of breast cancer.. 69. 2009
Inhibition of the p38 kinase suppresses the proliferation of human ER-negative breast cancer cells.. 69. 2009
Targeted disruption of the S1P2 sphingosine 1-phosphate receptor gene leads to diffuse large B-cell lymphoma formation.. 69. 2009
NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells.. 69. 2009
Whole-body sleeping beauty mutagenesis can cause penetrant leukemia/lymphoma and rare high-grade glioma without associated embryonic lethality.. 69. 2009
Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers.. 69. 2009
MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy.. 69. 2009
In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells.. 69. 2009
KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors.. 69. 2009
Epigenetic repression of DNA mismatch repair by inflammation and hypoxia in inflammatory bowel disease-associated colorectal cancer.. 69. 2009
Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis.. 69. 2009
3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma.. 69. 2009
CCL5-mediated endogenous antitumor immunity elicited by adoptively transferred lymphocytes and dendritic cell depletion.. 69. 2009
Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.. 69. 2009
MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors.. 69. 2009
Tumor necrosis factor-alpha and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice.. 69. 2009
Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition.. 69. 2009
Biological significance of prolactin in gynecologic cancers.. 69. 2009
Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.. 69. 2009
Src stimulates fibroblast growth factor receptor-2 shedding by an ADAM15 splice variant linked to breast cancer.. 69. 2009
Breast cancer metastasis: challenges and opportunities.. 69. 2009
A novel technology for the imaging of acidic prostate tumors by positron emission tomography.. 69. 2009
A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro.. 69. 2009
Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia.. 69. 2009
Immune rejection of mouse tumors expressing mutated self.. 69. 2009
SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer.. 69. 2009
Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition.. 69. 2009
Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes.. 69. 2009
Correlation analysis between single-nucleotide polymorphism and expression arrays in gliomas identifies potentially relevant target genes.. 69. 2009
TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy.. 69. 2009
Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer.. 69. 2009
Genome-wide promoter analysis of the SOX4 transcriptional network in prostate cancer cells.. 69. 2009
gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity.. 69. 2009
Distinct roles for mammalian target of rapamycin complexes in the fibroblast response to transforming growth factor-beta.. 69. 2009
Inhibition of DNA methyltransferase activates tumor necrosis factor alpha-induced monocytic differentiation in acute myeloid leukemia cells.. 69. 2009
Vascular endothelial growth factor-C and C-C chemokine receptor 7 in tumor cell-lymphatic cross-talk promote invasive phenotype.. 69. 2009
Cancer stem cells are enriched in the side population cells in a mouse model of glioma.. 68. 2008
Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma.. 68. 2008
SMAD6 contributes to patient survival in non-small cell lung cancer and its knockdown reestablishes TGF-beta homeostasis in lung cancer cells.. 68. 2008
Genetic predictors of MEK dependence in non-small cell lung cancer.. 68. 2008
Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability.. 68. 2008
Type 2 Bias of T cells expanded from the blood of melanoma patients switched to type 1 by IL-12p70 mRNA-transfected dendritic cells.. 68. 2008
The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation.. 68. 2008
Noninvasive molecular imaging of hypoxia in human xenografts: comparing hypoxia-induced gene expression with endogenous and exogenous hypoxia markers.. 68. 2008
Roles of idiotype-specific t cells in myeloma cell growth and survival: Th1 and CTL cells are tumoricidal while Th2 cells promote tumor growth.. 68. 2008
Disruption of NAD(P)H:quinone oxidoreductase 1 gene in mice leads to radiation-induced myeloproliferative disease.. 68. 2008
Pericentromeric instability and spontaneous emergence of human neoacrocentric and minute chromosomes in the alternative pathway of telomere lengthening.. 68. 2008
Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs.. 68. 2008
Kaiso contributes to DNA methylation-dependent silencing of tumor suppressor genes in colon cancer cell lines.. 68. 2008
Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity.. 68. 2008
Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation.. 68. 2008
The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth.. 68. 2008
Variants in the ATM gene associated with a reduced risk of contralateral breast cancer.. 68. 2008
Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage.. 68. 2008
A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model.. 68. 2008
Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.. 68. 2008
Nitrosoureas inhibit the stathmin-mediated migration and invasion of malignant glioma cells.. 68. 2008
Matrix metalloproteinase 9 is a mediator of epidermal growth factor-dependent e-cadherin loss in ovarian carcinoma cells.. 68. 2008
RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR.. 68. 2008
microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma.. 68. 2008
Sequential transcription factor targeting for diffuse large B-cell lymphomas.. 68. 2008
Variants of the adiponectin and adiponectin receptor 1 genes and breast cancer risk.. 68. 2008
Imaging transgene activity in vivo.. 68. 2008
Activator protein-1 transcription factors are associated with progression and recurrence of prostate cancer.. 68. 2008
Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer.. 68. 2008
The signatures of autozygosity among patients with colorectal cancer.. 68. 2008
Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib.. 68. 2008
Epitope landscape in breast and colorectal cancer.. 68. 2008
Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.. 68. 2008
p53-Dependent and p53-independent activation of autophagy by ARF.. 68. 2008
Circulating colony stimulating factor-1 and breast cancer risk.. 68. 2008
In vivo imaging and quantitation of adoptively transferred human antigen-specific T cells transduced to express a human norepinephrine transporter gene.. 67. 2007
3'-deoxy-3'-[18F]fluorothymidine positron emission tomography is a sensitive method for imaging the response of BRAF-dependent tumors to MEK inhibition.. 67. 2007
Common and distinct genomic events in sporadic colorectal cancer and diverse cancer types.. 67. 2007
Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma.. 67. 2007
Treatment of invasive retinoblastoma in a murine model using an oncolytic picornavirus.. 67. 2007
Integrative microarray analysis of pathways dysregulated in metastatic prostate cancer.. 67. 2007
Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer.. 67. 2007
Control of androgen receptor signaling in prostate cancer by the cochaperone small glutamine rich tetratricopeptide repeat containing protein alpha.. 67. 2007
Antitumor and antivascular effects of AVE8062 in ovarian carcinoma.. 67. 2007
The role of platelet/endothelial cell adhesion molecule 1 (CD31) and CD38 antigens in marrow microenvironmental retention of acute myelogenous leukemia cells.. 67. 2007
Tobacco smoke induces urokinase-type plasminogen activator and cell invasiveness: evidence for an epidermal growth factor receptor dependent mechanism.. 67. 2007
A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma.. 67. 2007
Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors.. 67. 2007
Expression of interleukin-13 receptor alpha2 in glioblastoma multiforme: implications for targeted therapies.. 67. 2007
In vivo role of NAD(P)H:quinone oxidoreductase 1 in metabolic activation of mitomycin C and bone marrow cytotoxicity.. 67. 2007
Expression of L1-CAM and ADAM10 in human colon cancer cells induces metastasis.. 67. 2007
Visualization of hypoxia in microscopic tumors by immunofluorescent microscopy.. 67. 2007
A polyepitope DNA vaccine targeted to Her-2/ErbB-2 elicits a broad range of human and murine CTL effectors to protect against tumor challenge.. 67. 2007
Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma.. 67. 2007
The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells.. 67. 2007
Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development.. 67. 2007
The inhibitory effect of (-)-epigallocatechin gallate on activation of the epidermal growth factor receptor is associated with altered lipid order in HT29 colon cancer cells.. 67. 2007
The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration.. 67. 2007
Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer.. 67. 2007
Positron emission tomography of herpes simplex virus 1 oncolysis.. 67. 2007
Engagement of collagen-binding integrins promotes matrix metalloproteinase-9-dependent E-cadherin ectodomain shedding in ovarian carcinoma cells.. 67. 2007
Inactivation of the candidate tumor suppressor par-4 in endometrial cancer.. 67. 2007
Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma.. 67. 2007
Adenovirus-mediated expression of a dominant negative Ku70 fragment radiosensitizes human tumor cells under aerobic and hypoxic conditions.. 67. 2007
Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer.. 67. 2007
Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model.. 66. 2006
Enforced expression of NUP98-HOXA9 in human CD34(+) cells enhances stem cell proliferation.. 66. 2006
Characterization of murine JAK2V617F-positive myeloproliferative disease.. 66. 2006
Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities.. 66. 2006
Reassessment of id1 protein expression in human mammary, prostate, and bladder cancers using a monospecific rabbit monoclonal anti-id1 antibody.. 66. 2006
Up-regulation of expression of the ubiquitin carboxyl-terminal hydrolase L1 gene in human airway epithelium of cigarette smokers.. 66. 2006
A genome-wide screen reveals functional gene clusters in the cancer genome and identifies EphA2 as a mitogen in glioblastoma.. 66. 2006
Combined stimulation with interleukin-18 and CpG induces murine natural killer dendritic cells to produce IFN-gamma and inhibit tumor growth.. 66. 2006
Transgenic mouse model for rapid pharmacodynamic evaluation of antiandrogens.. 66. 2006
High-resolution global genomic survey of 178 gliomas reveals novel regions of copy number alteration and allelic imbalances.. 66. 2006
Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells.. 66. 2006
Cytogenetic instability in ovarian epithelial cells from women at risk of ovarian cancer.. 66. 2006
Population-based study of natural variation in the melanocortin-1 receptor gene and melanoma.. 66. 2006
Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma.. 66. 2006
Farnesyltransferase inhibitors reverse taxane resistance.. 66. 2006
TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer.. 66. 2006
The isopeptidase USP2a protects human prostate cancer from apoptosis.. 66. 2006
p27Kip1 repression of ErbB2-induced mammary tumor growth in transgenic mice involves Skp2 and Wnt/beta-catenin signaling.. 66. 2006
Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells.. 66. 2006
The anti-CD25 monoclonal antibody 7G7/B6, armed with the alpha-emitter 211At, provides effective radioimmunotherapy for a murine model of leukemia.. 66. 2006
A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6.. 66. 2006
Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo.. 66. 2006
Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis.. 66. 2006
The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function.. 66. 2006
Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors.. 66. 2006
Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling.. 66. 2006
Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number.. 66. 2006
Mitogen-activated protein kinase phosphatase 2: a novel transcription target of p53 in apoptosis.. 66. 2006
Androgen-dependent regulation of Her-2/neu in prostate cancer cells.. 66. 2006
Flavopiridol targets c-KIT transcription and induces apoptosis in gastrointestinal stromal tumor cells.. 66. 2006
HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanism.. 66. 2006
MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner.. 66. 2006
Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity.. 66. 2006
Combined cDNA array comparative genomic hybridization and serial analysis of gene expression analysis of breast tumor progression.. 66. 2006
Adenoviral gene transfer of stromal cell-derived factor-1 to murine tumors induces the accumulation of dendritic cells and suppresses tumor growth.. 66. 2006
Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture.. 66. 2006
Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction.. 66. 2006
The secretory leukocyte protease inhibitor is a type 1 insulin-like growth factor receptor-regulated protein that protects against liver metastasis by attenuating the host proinflammatory response.. 66. 2006
Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3.. 66. 2006
The MYCN enigma: significance of MYCN expression in neuroblastoma.. 66. 2006
Endocytic recycling compartments altered in cisplatin-resistant cancer cells.. 66. 2006
Relationship of gene expression and chromosomal abnormalities in colorectal cancer.. 66. 2006
Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer.. 66. 2006
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.. 66. 2006
Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays.. 66. 2006
Down-regulation of stem cell genes, including those in a 200-kb gene cluster at 12p13.31, is associated with in vivo differentiation of human male germ cell tumors.. 66. 2006
Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.. 66. 2006
Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization.. 66. 2006
Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells.. 66. 2006
The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor as a therapeutic target for the treatment of Kaposi's sarcoma.. 66. 2006
Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line.. 65. 2005
Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma.. 65. 2005
Expression of the MutL homologue hMLH3 in human cells and its role in DNA mismatch repair.. 65. 2005
Rapamycin-sensitive pathway regulates mitochondrial membrane potential, autophagy, and survival in irradiated MCF-7 cells.. 65. 2005
Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer.. 65. 2005
Diminished expression of transcription factors nuclear factor kappaB and CCAAT/enhancer binding protein underlies a novel tumor evasion mechanism affecting macrophages of mammary tumor-bearing mice.. 65. 2005
Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.. 65. 2005
HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice.. 65. 2005
Critical function for ADAM9 in mouse prostate cancer.. 65. 2005
beta-Tubulin mutations are associated with resistance to 2-methoxyestradiol in MDA-MB-435 cancer cells.. 65. 2005
Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function.. 65. 2005
Contributions by MutL homologues Mlh3 and Pms2 to DNA mismatch repair and tumor suppression in the mouse.. 65. 2005
Targeted elimination of prostate cancer by genetically directed human T lymphocytes.. 65. 2005
Identification of a novel prostate tumor target, mindin/RG-1, for antibody-based radiotherapy of prostate cancer.. 65. 2005
Trastuzumab therapy for tamoxifen-stimulated endometrial cancer.. 65. 2005
Tomographic fluorescence mapping of tumor targets.. 65. 2005
A molecular classification of papillary renal cell carcinoma.. 65. 2005
Analysis of hypoxia-related gene expression in sarcomas and effect of hypoxia on RNA interference of vascular endothelial cell growth factor A.. 65. 2005
CDX2 polymorphisms, RNA expression, and risk of colorectal cancer.. 65. 2005
Tobacco smoke stimulates the transcription of amphiregulin in human oral epithelial cells: evidence of a cyclic AMP-responsive element binding protein-dependent mechanism.. 65. 2005
Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors.. 65. 2005
Efforts to control the errant products of a targeted in vivo generator.. 65. 2005
Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation.. 65. 2005
The G protein-coupled receptor S1P2 regulates Rho/Rho kinase pathway to inhibit tumor cell migration.. 65. 2005
The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase.. 65. 2005
Combined genetic assessment of transforming growth factor-beta signaling pathway variants may predict breast cancer risk.. 65. 2005
Fetal stromal-dependent paracrine and intracrine vascular endothelial growth factor-a/vascular endothelial growth factor receptor-1 signaling promotes proliferation and motility of human primary myeloma cells.. 65. 2005
Gene expression profiling allows distinction between primary and metastatic squamous cell carcinomas in the lung.. 65. 2005
EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma.. 65. 2005
Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells.. 65. 2005
Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation.. 65. 2005
IGFBP-3 is a direct target of transcriptional regulation by DeltaNp63alpha in squamous epithelium.. 65. 2005
Lower induction of p53 and decreased apoptosis in NQO1-null mice lead to increased sensitivity to chemical-induced skin carcinogenesis.. 65. 2005
An expression signature classifies chemotherapy-resistant pediatric osteosarcoma.. 65. 2005
Positive contribution of pathogenic mutations in the mitochondrial genome to the promotion of cancer by prevention from apoptosis.. 65. 2005
Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor.. 65. 2005
Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway.. 65. 2005
Levels of cyclooxygenase-2 are increased in the oral mucosa of smokers: evidence for the role of epidermal growth factor receptor and its ligands.. 65. 2005
Gene transfer-mediated pre-mRNA segmental trans-splicing as a strategy to deliver intracellular toxins for cancer therapy.. 65. 2005
Agents with selective estrogen receptor (ER) modulator activity induce apoptosis in vitro and in vivo in ER-negative glioma cells.. 64. 2004
Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells.. 64. 2004
Estrogen receptor genotypes and haplotypes associated with breast cancer risk.. 64. 2004
Survivin deregulation in beta-tubulin mutant ovarian cancer cells underlies their compromised mitotic response to taxol.. 64. 2004
Host acid sphingomyelinase regulates microvascular function not tumor immunity.. 64. 2004
Localization of cancer susceptibility genes by genome-wide single-nucleotide polymorphism linkage-disequilibrium mapping.. 64. 2004
Proinvasive properties of ovarian cancer ascites-derived membrane vesicles.. 64. 2004
Conditional deletion of Rb causes early stage prostate cancer.. 64. 2004
Molecular imaging of temporal dynamics and spatial heterogeneity of hypoxia-inducible factor-1 signal transduction activity in tumors in living mice.. 64. 2004
The Rgr oncogene induces tumorigenesis in transgenic mice.. 64. 2004
Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult t-cell leukemia.. 64. 2004
Oncolytic activity of p53-expressing conditionally replicative adenovirus AdDelta24-p53 against human malignant glioma.. 64. 2004
Uterine leiomyomata with t(10;17) disrupt the histone acetyltransferase MORF.. 64. 2004
Increased progesterone receptor expression in benign epithelium of BRCA1-related breast cancers.. 64. 2004
Dose-dependent effects of platelet-derived growth factor-B on glial tumorigenesis.. 64. 2004
High-resolution global profiling of genomic alterations with long oligonucleotide microarray.. 64. 2004
Akt stimulates aerobic glycolysis in cancer cells.. 64. 2004
Genome-wide profiling of papillary thyroid cancer identifies MUC1 as an independent prognostic marker.. 64. 2004
Proteasome-mediated destruction of the cyclin a/cyclin-dependent kinase 2 complex suppresses tumor cell growth in vitro and in vivo.. 64. 2004
interferon regulatory factor-1 mediates the proapoptotic but not cell cycle arrest effects of the steroidal antiestrogen ICI 182,780 (faslodex, fulvestrant).. 64. 2004
Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathway.. 64. 2004
Kallikrein 4 is a predominantly nuclear protein and is overexpressed in prostate cancer.. 64. 2004
A mimic of tumor rejection antigen-associated carbohydrates mediates an antitumor cellular response.. 64. 2004
Cancer and the microenvironment: myeloma-osteoclast interactions as a model.. 64. 2004
NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors.. 64. 2004
In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)-PE38 against breast cancer, osteosarcoma, and neuroblastoma.. 64. 2004
Novel nanosensors for rapid analysis of telomerase activity.. 64. 2004
Cathepsin B mediates caspase-independent cell death induced by microtubule stabilizing agents in non-small cell lung cancer cells.. 64. 2004
Cellular and genetic characterization of human adult bone marrow-derived neural stem-like cells: a potential antiglioma cellular vector.. 63. 2003
Identification of prognostic markers in bone sarcomas using proton-decoupled phosphorus magnetic resonance spectroscopy.. 63. 2003
A prospective study of XRCC1 haplotypes and their interaction with plasma carotenoids on breast cancer risk.. 63. 2003
Combination treatment with 17-N-allylamino-17-demethoxy geldanamycin and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroids.. 63. 2003
The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells.. 63. 2003
Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen.. 63. 2003
Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors.. 63. 2003
Early postoperative peripheral blood reverse transcription PCR assay for prostate-specific antigen is associated with prostate cancer progression in patients undergoing radical prostatectomy.. 63. 2003
NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer.. 63. 2003
Array comparative genome hybridization for tumor classification and gene discovery in mouse models of malignant melanoma.. 63. 2003
Enhancing targeted radiotherapy by copper(II)diacetyl- bis(N4-methylthiosemicarbazone) using 2-deoxy-D-glucose.. 63. 2003
Genome-wide array CGH analysis of murine neuroblastoma reveals distinct genomic aberrations which parallel those in human tumors.. 63. 2003
Genome-wide loss of heterozygosity analysis from laser capture microdissected prostate cancer using single nucleotide polymorphic allele (SNP) arrays and a novel bioinformatics platform dChipSNP.. 63. 2003
Targeted actinium-225 in vivo generators for therapy of ovarian cancer.. 63. 2003
Comparison of immunohistochemistry with reverse transcription-PCR for the detection of micrometastatic prostate cancer in lymph nodes.. 63. 2003
Genome-wide analysis of gene expression associated with MYCN in human neuroblastoma.. 63. 2003
Microvascular function regulates intestinal crypt response to radiation.. 63. 2003
Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues.. 63. 2003
Deficiency of kinase suppressor of Ras1 prevents oncogenic ras signaling in mice.. 63. 2003
Polarization of Valpha24+ Vbeta11+ natural killer T cells of healthy volunteers and cancer patients using alpha-galactosylceramide-loaded and environmentally instructed dendritic cells.. 63. 2003
Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse.. 63. 2003
A three-dimensional tumor cell defect in activating autologous CTLs is associated with inefficient antigen presentation correlated with heat shock protein-70 down-regulation.. 63. 2003
Adenovirus-mediated heat-activated antisense Ku70 expression radiosensitizes tumor cells in vitro and in vivo.. 63. 2003
Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo.. 63. 2003
Prostate-specific membrane antigen association with filamin A modulates its internalization and NAALADase activity.. 63. 2003
Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol.. 63. 2003
Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma.. 63. 2003
Twist is up-regulated in response to Wnt1 and inhibits mouse mammary cell differentiation.. 63. 2003
Genetic determinants of malignancy in a mouse model for oligodendroglioma.. 63. 2003
High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.. 63. 2003
Monoallelic up-regulation of the imprinted H19 gene in airway epithelium of phenotypically normal cigarette smokers.. 63. 2003
Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance.. 63. 2003
The homeotic protein Six3 is a coactivator of the nuclear receptor NOR-1 and a corepressor of the fusion protein EWS/NOR-1 in human extraskeletal myxoid chondrosarcomas.. 63. 2003
Immunotoxin resistance in multidrug resistant cells.. 63. 2003
Sequence-dependent synergistic cytotoxicity of ecteinascidin-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo.. 62. 2002
Genomic and expression analysis of the 12p11-p12 amplicon using EST arrays identifies two novel amplified and overexpressed genes.. 62. 2002
Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy.. 62. 2002
Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and (90)Y-labeled 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-biotin.. 62. 2002
Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer.. 62. 2002
Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt.. 62. 2002
Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts.. 62. 2002
Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility.. 62. 2002
Proinflammatory cytokines block growth of breast cancer cells by impairing signals from a growth factor receptor.. 62. 2002
Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases.. 62. 2002
Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease.. 62. 2002
Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).. 62. 2002
Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth.. 62. 2002
The N-ras proto-oncogene can suppress the malignant phenotype in the presence or absence of its oncogene.. 62. 2002
A hereditary nonpolyposis colorectal carcinoma case associated with hypermethylation of the MLH1 gene in normal tissue and loss of heterozygosity of the unmethylated allele in the resulting microsatellite instability-high tumor.. 62. 2002
Average midrange ultraviolet radiation flux and time outdoors predict melanoma risk.. 62. 2002
Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets.. 62. 2002
Late activation of apoptotic pathways plays a negligible role in mediating the cytotoxic effects of discodermolide and epothilone B in non-small cell lung cancer cells.. 62. 2002
A preliminary transcriptome map of non-small cell lung cancer.. 62. 2002
Evaluation of microsatellite instability and immunohistochemistry for the prediction of germ-line MSH2 and MLH1 mutations in hereditary nonpolyposis colon cancer families.. 62. 2002
Genotoxic exposure is associated with alterations in glucose uptake and metabolism.. 62. 2002
Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway.. 62. 2002
Involvement of membrane signaling in the bystander effect in irradiated cells.. 62. 2002
Novel regions of allelic imbalance identified by genome-wide analysis of neuroblastoma.. 62. 2002
Retinol metabolism and lecithin:retinol acyltransferase levels are reduced in cultured human prostate cancer cells and tissue specimens.. 62. 2002
Mutation profiling of mismatch repair-deficient colorectal cncers using an in silico genome scan to identify coding microsatellites.. 62. 2002
retSDR1, a short-chain retinol dehydrogenase/reductase, is retinoic acid-inducible and frequently deleted in human neuroblastoma cell lines.. 62. 2002
NAD(P)H and collagen as in vivo quantitative fluorescent biomarkers of epithelial precancerous changes.. 62. 2002
Copper-64-pyruvaldehyde-bis(N(4)-methylthiosemicarbazone) for the prevention of tumor growth at wound sites following laparoscopic surgery: monitoring therapy response with microPET and magnetic resonance imaging.. 62. 2002
In vivo analysis of human multidrug resistance protein 1 (MRP1) activity using transient expression of fluorescently tagged MRP1.. 62. 2002
Growth factor requirements and basal phenotype of an immortalized mammary epithelial cell line.. 62. 2002
Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients.. 62. 2002
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.. 61. 2001
KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.. 61. 2001
P-glycoprotein does not reduce substrate concentration from the extracellular leaflet of the plasma membrane in living cells.. 61. 2001
The distinct spectra of tumor-associated Apc mutations in mismatch repair-deficient Apc1638N mice define the roles of MSH3 and MSH6 in DNA repair and intestinal tumorigenesis.. 61. 2001
Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors.. 61. 2001
HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma.. 61. 2001
A nonsense mutation in MLH1 causes exon skipping in three unrelated HNPCC families.. 61. 2001
The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.. 61. 2001
Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis.. 61. 2001
Neuroblastic and Schwannian stromal cells of neuroblastoma are derived from a tumoral progenitor cell.. 61. 2001
In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR).. 61. 2001
The transcriptional repressor of p16/Ink4a, Id1, is up-regulated in early melanomas.. 61. 2001
Alterations of p14ARF, p53, and p73 genes involved in the E2F-1-mediated apoptotic pathways in non-small cell lung carcinoma.. 61. 2001
The Src-suppressed C kinase substrate, SSeCKS, is a potential metastasis inhibitor in prostate cancer.. 61. 2001
Ny-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade.. 61. 2001
Molecular cytogenetic characterization of head and neck squamous cell carcinoma and refinement of 3q amplification.. 61. 2001
Molecular identification of latent precancers in histologically normal endometrium.. 61. 2001
The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines.. 61. 2001
Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors.. 61. 2001
Neutral endopeptidase inhibits neuropeptide-mediated transactivation of the insulin-like growth factor receptor-Akt cell survival pathway.. 61. 2001
Characterization of molecular abnormalities in human fibroblastic neoplasms: a model for genotype-phenotype association in soft tissue tumors.. 61. 2001
Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells.. 61. 2001
Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells.. 61. 2001
Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.. 61. 2001
Adenovirus-mediated transfer of inducible caspases: a novel "death switch" gene therapeutic approach to prostate cancer.. 61. 2001
Angiogenesis and prostate cancer: identification of a molecular progression switch.. 61. 2001
Reduced levels of retinyl esters and vitamin A in human renal cancers.. 61. 2001
Identification of a tissue-specific putative transcription factor in breast tissue by serological screening of a breast cancer library.. 61. 2001
Response of LNCaP spheroids after treatment with an alpha-particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591).. 61. 2001
The gene for the axonal cell adhesion molecule TAX-1 is amplified and aberrantly expressed in malignant gliomas.. 61. 2001
A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles.. 61. 2001
Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo.. 61. 2001
Nonhomologous end-joining of ionizing radiation-induced DNA double-stranded breaks in human tumor cells deficient in BRCA1 or BRCA2.. 61. 2001
A role for the integrin alphavbeta8 in the negative regulation of epithelial cell growth.. 60. 2000
Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria-controlled manner in the non-small cell lung cancer cell line NCI-H460.. 60. 2000
Detection of metastatic prostate cancer using a splice variant-specific reverse transcriptase-polymerase chain reaction assay for human glandular kallikrein.. 60. 2000
Neutral endopeptidase promotes phorbol ester-induced apoptosis in prostate cancer cells by inhibiting neuropeptide-induced protein kinase C delta degradation.. 60. 2000
Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial.. 60. 2000
Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells.. 60. 2000
An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer.. 60. 2000
Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1.. 60. 2000
In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen.. 60. 2000
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.. 60. 2000
Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest.. 60. 2000
Use of phosphorous-31 nuclear magnetic resonance spectroscopy to determine safe timing of chemotherapy after hepatic resection.. 60. 2000
Differences of biodistribution, pharmacokinetics, and tumor targeting between interleukins 2 and 15.. 60. 2000
Serological cloning of a melanocyte rab guanosine 5'-triphosphate-binding protein and a chromosome condensation protein from a melanoma complementary DNA library.. 60. 2000
CD59 expressed on a tumor cell surface modulates decay-accelerating factor expression and enhances tumor growth in a rat model of human neuroblastoma.. 60. 2000
Levels of E2F-1 expression are higher in lung metastasis of colon cancer as compared with hepatic metastasis and correlate with levels of thymidylate synthase.. 60. 2000
Ligand responsiveness in human prostate cancer: structural analysis of mutant androgen receptors from LNCaP and CWR22 tumors.. 60. 2000
Cdr2, a target antigen of naturally occuring human tumor immunity, is widely expressed in gynecological tumors.. 60. 2000
E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse.. 60. 2000
Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases.. 60. 2000
DNA-dependent protein kinase stimulates an independently active, nonhomologous, end-joining apparatus.. 60. 2000
Androgen receptor mutations in prostate cancer.. 60. 2000
Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture.. 60. 2000
Radiation-induced apoptosis of endothelial cells in the murine central nervous system: protection by fibroblast growth factor and sphingomyelinase deficiency.. 60. 2000
Cancer-testis antigens and ING1 tumor suppressor gene product are breast cancer antigens: characterization of tissue-specific ING1 transcripts and a homologue gene.. 59. 1999
In vivo fluence rate and fractionation effects on tumor response and photobleaching: photodynamic therapy with two photosensitizers in an orthotopic rat tumor model.. 59. 1999
Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest.. 59. 1999
Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker.. 59. 1999
TbetaR-I(6A) is a candidate tumor susceptibility allele.. 59. 1999
Imaging adenoviral-mediated herpes virus thymidine kinase gene transfer and expression in vivo.. 59. 1999
Reversal of radiation resistance in LNCaP cells by targeting apoptosis through ceramide synthase.. 59. 1999
Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process.. 59. 1999
Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models.. 59. 1999
Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma.. 59. 1999
Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage.. 59. 1999
Anhydroretinol induces oxidative stress and cell death.. 59. 1999
Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.. 59. 1999
Dead or dying: necrosis versus apoptosis in caspase-deficient human renal cell carcinoma.. 59. 1999
Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN.. 59. 1999
CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression.. 59. 1999
Overexpression of cyclins D1 and E is frequent in bronchial preneoplasia and precedes squamous cell carcinoma development.. 59. 1999
HRad17, a human homologue of the Schizosaccharomyces pombe checkpoint gene rad17, is overexpressed in colon carcinoma.. 59. 1999
A mouse mammary tumor virus-Wnt-1 transgene induces mammary gland hyperplasia and tumorigenesis in mice lacking estrogen receptor-alpha.. 59. 1999
Differential transactivation by alternative EWS-FLI1 fusion proteins correlates with clinical heterogeneity in Ewing's sarcoma.. 59. 1999
Ovarian carcinoma regulation of matrix metalloproteinase-2 and membrane type 1 matrix metalloproteinase through beta1 integrin.. 59. 1999
Transcriptional activation of cyclooxygenase-2 in Wnt-1-transformed mouse mammary epithelial cells.. 59. 1999
Tumorigenesis in Mlh1 and Mlh1/Apc1638N mutant mice.. 59. 1999
Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer.. 59. 1999
Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck.. 59. 1999
Using computerized video time lapse for quantifying cell death of X-irradiated rat embryo cells transfected with c-myc or c-Ha-ras.. 59. 1999
A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity.. 59. 1999
The pharmacokinetic characteristics of glycolated humanized anti-Tac Fabs are determined by their isoelectric points.. 59. 1999
A multi-institutional study confirms the presence and expression of simian virus 40 in human malignant mesotheliomas.. 58. 1998
Chromosomal amplification is associated with cisplatin resistance of human male germ cell tumors.. 58. 1998
Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography.. 58. 1998
Reversal of CPT-11 resistance of lung cancer cells by adenovirus-mediated gene transfer of the human carboxylesterase cDNA.. 58. 1998
Constitutive and antibody-induced internalization of prostate-specific membrane antigen.. 58. 1998
Identification of genes expressed differentially by LNCaP or PC-3 prostate cancer cell lines.. 58. 1998
Bcl-xL is phosphorylated in malignant cells following microtubule disruption.. 58. 1998
Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers.. 58. 1998
PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma.. 58. 1998
Viral vector-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA.. 58. 1998
No association of the I1307K APC allele with ovarian cancer risk in Ashkenazi Jews.. 58. 1998
Positron emission tomography of a human prostate cancer xenograft: association of changes in deoxyglucose accumulation with other measures of outcome following androgen withdrawal.. 58. 1998
Antibodies against GD2 ganglioside can eradicate syngeneic cancer micrometastases.. 58. 1998
Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.. 58. 1998
Type I transforming growth factor beta receptor maps to 9q22 and exhibits a polymorphism and a rare variant within a polyalanine tract.. 58. 1998
Allelic deletion analysis of the FHIT gene predicts poor survival in non-small cell lung cancer.. 58. 1998
Aminosyn II effectively blocks renal uptake of 18F-labeled anti-tac disulfide-stabilized Fv.. 58. 1998
12-O-tetradecanoylphorbol-13-acetate-induced apoptosis in LNCaP cells is mediated through ceramide synthase.. 58. 1998
A Bcl-xL transgene promotes malignant conversion of chemically initiated skin papillomas.. 58. 1998
4-Oxoretinol, a metabolite of retinol in the human promyelocytic leukemia cell line NB4, induces cell growth arrest and granulocytic differentiation.. 58. 1998
BRCA-associated breast cancer: absence of a characteristic immunophenotype.. 58. 1998
Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma.. 58. 1998
Uroplakin II gene is expressed in transitional cell carcinoma but not in bilharzial bladder squamous cell carcinoma: alternative pathways of bladder epithelial differentiation and tumor formation.. 58. 1998
Detection of tumor response to chemotherapy by 1H nuclear magnetic resonance spectroscopy: effect of 5-fluorouracil on lactate levels in radiation-induced fibrosarcoma 1 tumors.. 58. 1998
Human lung cancer antigens recognized by autologous antibodies: definition of a novel cDNA derived from the tumor suppressor gene locus on chromosome 3p21.3.. 58. 1998
Novel triterpenoids suppress inducible nitric oxide synthase (iNOS) and inducible cyclooxygenase (COX-2) in mouse macrophages.. 58. 1998
Metabolism of all-trans-retinol in normal human cell strains and squamous cell carcinoma (SCC) lines from the oral cavity and skin: reduced esterification of retinol in SCC lines.. 58. 1998
Posttranscriptional regulation of protein expression in human epithelial carcinoma cells by adenine-uridine-rich elements in the 3'-untranslated region of tumor necrosis factor-alpha messenger RNA.. 57. 1997
Apc gene mutation is associated with a dominant-negative effect upon intestinal cell migration.. 57. 1997
Androgen-independent prostate cancer progression in the TRAMP model.. 57. 1997
Human breast cancer cells and normal mammary epithelial cells: retinol metabolism and growth inhibition by the retinol metabolite 4-oxoretinol.. 57. 1997
Quantitation of metabolic and radiobiological effects of 6-aminonicotinamide in RIF-1 tumor cells in vitro.. 57. 1997
Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium.. 57. 1997
Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer.. 57. 1997
Biodistribution of 125I-labeled des(1-3) insulin-like growth factor I in tumor-bearing nude mice and its in vitro catabolism.. 57. 1997
Two cytodifferentiation agent-induced pathways, differentiation and apoptosis, are distinguished by the expression of human papillomavirus 16 E7 in human bladder carcinoma cells.. 57. 1997
Expression of the tumor-associated gene MN: a potential biomarker for human renal cell carcinoma.. 57. 1997
FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations.. 57. 1997
Improved biodistribution of 125I-labeled anti-Tac disulfide-stabilized Fv fragment by blocking its binding to the alpha subunit of the interleukin 2 receptor in the circulation with preinjected humanized anti-Tac IgG.. 57. 1997
Basic fibroblast growth factor causes growth arrest in MCF-7 human breast cancer cells while inducing both mitogenic and inhibitory G1 events.. 57. 1997
Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children.. 57. 1997
Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors.. 57. 1997
The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas.. 57. 1997
Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines.. 57. 1997
Glutathione metabolism in patients with non-small cell lung cancers.. 57. 1997
Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death.. 57. 1997
Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells.. 56. 1996
Apoptosis induced by X-irradiation of rec-myc cells is postmitotic and not predicted by the time after irradiation or behavior of sister cells.. 56. 1996
Metastatic prostate cancer in a transgenic mouse.. 56. 1996
Noninvasive imaging of herpes virus thymidine kinase gene transfer and expression: a potential method for monitoring clinical gene therapy.. 56. 1996
Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145.. 56. 1996
Brain-derived neurotrophic factor protects neuroblastoma cells from vinblastine toxicity.. 56. 1996
L-lysine effectively blocks renal uptake of 125I- or 99mTc-labeled anti-Tac disulfide-stabilized Fv fragment.. 56. 1996
Metabolic phenotypes of retinoic acid and the risk of lung cancer.. 56. 1996
Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis.. 56. 1996
Stable transfection of the P-glycoprotein promoter reproduces the endogenous overexpression phenotype: the role of MED-1.. 56. 1996
Telomerase activity is repressed during differentiation of maturation-sensitive but not resistant human tumor cell lines.. 56. 1996
Corticotropin-releasing factor decreases vasogenic brain edema.. 56. 1996
Reexpression of thyroid peroxidase in a derivative of an undifferentiated thyroid carcinoma cell line by introduction of wild-type p53.. 56. 1996
Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins.. 55. 1995
Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias.. 55. 1995
A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines.. 55. 1995
Biodistribution of 18F- and 125I-labeled anti-Tac disulfide-stabilized Fv fragments in nude mice with interleukin 2 alpha receptor-positive tumor xenografts.. 55. 1995
In vivo gene therapy with p53 or p21 adenovirus for prostate cancer.. 55. 1995
Pyruvate utilization, phosphocholine and adenosine triphosphate (ATP) are markers of human breast tumor progression: a 31P- and 13C-nuclear magnetic resonance (NMR) spectroscopy study.. 55. 1995
Radiation-induced apoptosis: effects of cell age and dose fractionation.. 55. 1995
Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer.. 55. 1995
Thrombopoietin receptor expression in human cancer cell lines and primary tissues.. 55. 1995
Improved tumor radioimmunodetection using a single-chain Fv and gamma-interferon: potential clinical applications for radioimmunoguided surgery and gamma scanning.. 55. 1995
RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-gamma.. 55. 1995
Aberrant expression of p53 or the epidermal growth factor receptor is frequent in early bronchial neoplasia and coexpression precedes squamous cell carcinoma development.. 55. 1995
In vitro and in vivo 31P nuclear magnetic resonance measurements of metabolic changes post radiation.. 55. 1995
p27Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors.. 55. 1995
Suppression of Bcl-2 messenger RNA production may mediate apoptosis after ionizing radiation, tumor necrosis factor alpha, and ceramide.. 55. 1995
9-Cis retinoic acid inhibits growth of breast cancer cells and down-regulates estrogen receptor RNA and protein.. 54. 1994
Mcl-1, a member of the Bcl-2 family, delays apoptosis induced by c-Myc overexpression in Chinese hamster ovary cells.. 54. 1994
Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays.. 54. 1994
Ex vivo two-dimensional proton nuclear magnetic resonance spectroscopy of smooth muscle tumors: advantages of total correlated spectroscopy over homonuclear J-correlated spectroscopy.. 54. 1994
Loss of heterozygosity identifies multiple sites of allelic deletions on chromosome 1 in human male germ cell tumors.. 54. 1994
Simultaneous dose escalation and schedule intensification of carboplatin-based chemotherapy using peripheral blood progenitor cells and filgrastim: a phase I trial.. 54. 1994
Enhancer sequences of the DF3 gene regulate expression of the herpes simplex virus thymidine kinase gene and confer sensitivity of human breast cancer cells to ganciclovir.. 54. 1994
Clonal composition of human adrenocortical neoplasms.. 54. 1994
Radiation dose-dependent changes in tumor metabolism measured by 31P nuclear magnetic resonance spectroscopy.. 54. 1994
Replication error-type genetic instability at 1q42-43 in human male germ cell tumors.. 54. 1994
Chromosome 9 allelic losses and microsatellite alterations in human bladder tumors.. 54. 1994
Protein kinase C mediates basic fibroblast growth factor protection of endothelial cells against radiation-induced apoptosis.. 54. 1994
Antibody response to murine anti-GD2 monoclonal antibodies: correlation with patient survival.. 54. 1994
Elevated plasma lipid peroxide content correlates with rapid plasma clearance of all-trans-retinoic acid in patients with advanced cancer.. 54. 1994
Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas.. 54. 1994
Allelic deletions in renal tumors: histopathological correlations.. 53. 1993
Growth hormone administration preserves lean body mass in sarcoma-bearing rats treated with doxorubicin.. 53. 1993
p53 protein accumulates frequently in early bronchial neoplasia.. 53. 1993
Dietary fenretinide, a synthetic retinoid, decreases the tumor incidence and the tumor mass of ras+myc-induced carcinomas in the mouse prostate reconstitution model system.. 53. 1993
Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors.. 53. 1993
Potentiation of a three drug chemotherapy regimen by radiation.. 53. 1993
Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin.. 53. 1993
Modeling the development of metastases from primary and locally recurrent tumors: comparison with a clinical data base for prostatic cancer.. 53. 1993
Preclinical evaluation of 111In-labeled B3 monoclonal antibody: biodistribution and imaging studies in nude mice bearing human epidermoid carcinoma xenografts.. 53. 1993
Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung.. 53. 1993
Presence of point mutations in the N-ras gene in radiation-transformed rat embryo cells.. 53. 1993
Time course of induction of metabolism of all-trans-retinoic acid and the up-regulation of cellular retinoic acid-binding protein.. 53. 1993
Expansion of the epithelial cell proliferative compartment and frequency of adenomatous polyps in the colon correlate with the strength of family history of colorectal cancer.. 53. 1993
MDM2 gene amplification in metastatic osteosarcoma.. 53. 1993
Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies.. 52. 1992
Retroviral vector-mediated lymphokine gene transfer into human renal cancer cells.. 52. 1992
Immunization of colorectal cancer patients with modified ovine submaxillary gland mucin and adjuvants induces IgM and IgG antibodies to sialylated Tn.. 52. 1992
Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression.. 52. 1992
Quantitative changes in tumor metabolism, partial pressure of oxygen, and radiobiological oxygenation status postradiation.. 52. 1992
Biochemical modulation of tumor cell energy: regression of advanced spontaneous murine breast tumors with a 5-fluorouracil-containing drug combination.. 52. 1992
Effect of systemic hyperinsulinemia in cancer patients.. 52. 1992
Multiple biological markers in germ cell tumor patients treated with platinum-based chemotherapy.. 52. 1992
Neuromedin B is present in lung cancer cell lines.. 52. 1992
Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression.. 52. 1992
Mechanisms of natural resistance to antifolates in human soft tissue sarcomas.. 52. 1992
Expression of HLA-A,B,C antigens on primary and metastatic tumor cell populations of human carcinomas.. 51. 1991
alpha-Interferon down-regulates epidermal growth factor receptors on renal carcinoma cells: relation to cellular responsiveness to the antiproliferative action of alpha-interferon.. 51. 1991
Molecular genetic alterations in superficial and locally advanced human bladder cancer.. 51. 1991
Clinically effective monoclonal antibody 3F8 mediates nonoxidative lysis of human neuroectodermal tumor cells by polymorphonuclear leukocytes.. 51. 1991
Growth factor messenger RNA expression by human breast fibroblasts from benign and malignant lesions.. 51. 1991
Induction of growth factor RNA expression in human malignant melanoma: markers of transformation.. 51. 1991
Abnormal expression of retinoic acid receptors and keratin 19 by human oral and epidermal squamous cell carcinoma cell lines.. 51. 1991
DNA ploidy by image analysis of individual foci of prostate cancer: a preliminary report.. 51. 1991
Angiogenesis determines blood flow, metabolism, growth rate, and ATPase kinetics of tumors growing in an irradiated bed: 31P and 2H nuclear magnetic resonance studies.. 51. 1991
Role of low-affinity Fc receptors in antibody-dependent tumor cell phagocytosis by human monocyte-derived macrophages.. 51. 1991
Production of large amounts of hydrogen peroxide by human tumor cells.. 51. 1991
Tumor-induced alterations in tissue lipoprotein lipase activity and mRNA levels.. 51. 1991
Phase I evaluation of a combination of monoclonal antibody R24 and interleukin 2 in patients with metastatic melanoma.. 50. 1990
Changes in radiation sensitization induced by Fluosol-DA as measured by 31P nuclear magnetic resonance spectroscopy.. 50. 1990
Estrogen and progesterone receptors in bronchogenic carcinoma.. 50. 1990
11p13-15 is a specific region of chromosomal rearrangement in gastric and esophageal adenocarcinomas.. 50. 1990
Gene amplification in gastric and esophageal adenocarcinomas.. 50. 1990
Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors.. 50. 1990
Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2.. 50. 1990
Establishment and characterization of a human adrenocortical carcinoma cell line that expresses multiple pathways of steroid biosynthesis.. 50. 1990
Establishment and characterization of human renal cancer and normal kidney cell lines.. 50. 1990
In vivo administration of interferon alpha and interleukin 2 induces proliferation of lymphoid cells in the organs of mice.. 50. 1990
Classifying clinical severity to help solve problems of stage migration in nonconcurrent comparisons of lung cancer therapy.. 50. 1990
Thermal response of oncogene-transfected rat cells.. 50. 1990
Antiproliferative and antitumor effects of alpha-interferon in renal cell carcinomas: correlation with the expression of a kidney-associated differentiation glycoprotein.. 50. 1990
Characterization of glutathione S-transferase expression in lymphocytes from chronic lymphocytic leukemia patients.. 50. 1990
Manipulation of oxygen radical-scavenging capacity in mice alters host sensitivity to tumor necrosis factor toxicity but does not interfere with its antitumor efficacy.. 50. 1990
Studies of effects of recombinant human tumor necrosis factor on autochthonous tumor and transplanted normal tissue in mice.. 50. 1990
Protein kinase C-induced stimulation or inhibition of cellular proliferation in a murine macrophage tumor cell line.. 50. 1990
Light chain variants of an IgG3 anti-GD3 monoclonal antibody and the relationship among avidity, effector functions, tumor targeting, and antitumor activity.. 50. 1990
Selection and preliminary characterization of variant lines of a murine macrophage tumor resistant to the antiproliferative effects of phorbol esters.. 50. 1990
Radioimmunotherapy in experimental animal models: principles derived from models.. 50. 1990
Insulin-like growth factor receptor expression and function in human breast cancer.. 50. 1990
Karyometric marker features in normal-appearing glands adjacent to human colonic adenocarcinoma.. 50. 1990
Synergistic effect of the v-myc oncogene with H-ras on radioresistance.. 50. 1990
Analysis of a mouse monoclonal antibody that reacts with a specific region of the human proximal tubule and subsets renal cell carcinomas.. 49. 1989
Multidrug resistance in a human leukemic cell line selected for resistance to trimetrexate.. 49. 1989
Effects of irradiation on the release of growth factors from cultured bovine, porcine, and human endothelial cells.. 49. 1989
Phase I trial of N-(phosphonacetyl)-L-aspartate, methotrexate, and 5-fluorouracil with leucovorin rescue in patients with advanced cancer.. 49. 1989
Local distribution and concentration of intravenously injected 131I-9.2.27 monoclonal antibody in human malignant melanoma.. 49. 1989
Mouse cellular retinoic acid binding protein: cloning, complementary DNA sequence, and messenger RNA expression during the retinoic acid-induced differentiation of F9 wild type and RA-3-10 mutant teratocarcinoma cells.. 49. 1989
Decrease in interleukin 2-induced vascular leakage in the lungs of mice by administration of recombinant interleukin 1 alpha in vivo.. 49. 1989
4-demethoxydaunorubicin (idarubicin) in combination with 1-beta-D-arabinofuranosylcytosine in the treatment of relapsed or refractory acute leukemia.. 49. 1989
Blood group-related antigens in human kidney: modulation of Lewis determinants in renal cell carcinoma.. 49. 1989
A Gompertzian model of human breast cancer growth.. 48. 1988
Insulin-like growth factor II mRNA expression in human breast cancer.. 48. 1988
FSaII mouse tumor metabolic changes with different doses of glucose measured by 31P nuclear magnetic resonance.. 48. 1988
Measurement of local Mr 97,000 and 250,000 protein antigen concentration in sections of human melanoma tumor using in vitro quantitative autoradiography.. 48. 1988
Phase I trial and clinical pharmacological evaluation of 10-ethyl-10-deazaaminopterin in adult patients with advanced cancer.. 48. 1988
Blood group-related antigens in human germ cell tumors.. 48. 1988
Augmentation of tumor targeting in a line of glioma-specific mouse cytotoxic T-lymphocytes by retroviral expression of mouse gamma-interferon complementary DNA.. 48. 1988
Preclinical studies on the pharmacokinetic properties of human monoclonal antibodies to colorectal cancer and their use for detection of tumors.. 48. 1988
Blood group-related antigens in human urothelium: enhanced expression of precursor, LeX, and LeY determinants in urothelial carcinoma.. 48. 1988
Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II.. 48. 1988
Cytotoxic effects of m-[131I]- and m-[125I]iodobenzylguanidine on the human neuroblastoma cell lines SK-N-SH and SK-N-LO.. 48. 1988
Anticarcinoma activity of rhodamine 123 against a murine renal adenocarcinoma.. 48. 1988
Randomized trial of combined modality therapy with and without thymosin fraction V in the treatment of small cell lung cancer.. 48. 1988
Expression of an antigen in small cell lung carcinoma lines detected by antibodies from patients with paraneoplastic dorsal root ganglionpathy.. 48. 1988
Augmentation of activity of cis-diamminedichloroplatinum(II) and mitomycin C by interferon in human malignant mesothelioma xenografts in nude mice.. 48. 1988
Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma.. 47. 1987
Tumor behavior in transitional cell carcinoma of the bladder in relation to chromosomal markers and histopathology.. 47. 1987
Effects of intermittent diethylstilbestrol diphosphate administration on the R3327 rat prostatic carcinoma.. 47. 1987
Fate of gamma-interferon-activated killer blood monocytes adoptively transferred into the abdominal cavity of patients with peritoneal carcinomatosis.. 47. 1987
Immunolymphoscintigraphy and the dose dependence of 111In-labeled T101 monoclonal antibody in patients with cutaneous T-cell lymphoma.. 47. 1987
Localization of GD2-specific monoclonal antibody 3F8 in human osteosarcoma.. 47. 1987
Isolation of amplified and overexpressed DNA sequences from adriamycin-resistant human breast cancer cells.. 47. 1987
Sodium transport in a mouse model of colonic carcinogenesis.. 47. 1987
Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72.3) in patients with carcinoma.. 47. 1987
Cytotoxic activity of a polyamine analogue, monoaziridinylputrescine, against the PC-3 human prostatic carcinoma cell line.. 47. 1987
Immunolymphoscintigraphy of pulmonary and mediastinal lymph nodes in dogs: a new approach to lung cancer imaging.. 47. 1987
Phase I and clinical pharmacological study of 4-demethoxydaunorubicin (idarubicin) in children with advanced cancer.. 47. 1987
Presence of chromosomal abnormalities and lack of AIDS retrovirus DNA sequences in AIDS-associated Kaposi's sarcoma.. 46. 1986
Morphological, biological, biochemical, and karyotypic characteristics of human pancreatic ductal adenocarcinoma Capan-2 in tissue culture and the nude mouse.. 46. 1986
Pharmacokinetics of cis-diamminedichloroplatinum(II) after administration in hypertonic saline.. 46. 1986
Gallium nitrate for acute treatment of cancer-related hypercalcemia: clinicopharmacological and dose response analysis.. 46. 1986
Increased N-myc expression following progressive growth of human neuroblastoma.. 46. 1986
Regulation of the proliferation of the established human monoblast cell line, U937, at the single cell level.. 46. 1986
Binding characteristics and biological activity of 17 alpha-[125I]iodovinyl-11 beta-methoxyestradiol, an estrogen receptor-binding radiopharmaceutical, in human breast cancer cells (MCF-7).. 46. 1986
Etoposide induced blood-brain barrier disruption in rats: duration of opening and histological sequelae.. 46. 1986
Immunological variables as predictors of prognosis in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome.. 46. 1986
Basal amino acid concentrations and the response to incremental glucose infusion in tumor bearing rats.. 45. 1985
Specific uptake of m-[125I]iodobenzylguanidine in the human neuroblastoma cell line SK-N-SH.. 45. 1985
Eradication of neuroblastoma cells in vitro by monoclonal antibody and human complement: method for purging autologous bone marrow.. 45. 1985
Effect of intravesical Bacillus Calmette-Guérin on detection of a urothelial differentiation antigen in exfoliated cells of carcinoma in situ of the human urinary bladder.. 45. 1985
Spectrum of Kaposi's sarcoma in the epidemic of AIDS.. 45. 1985
Staphylococcal Protein A column: correlation of mitogenicity of perfused plasma with clinical response.. 45. 1985
Alterations in the activity and isozymic profile of human phosphofructokinase during malignant transformation in vivo and in vitro: transformation- and progression-linked discriminants of malignancy.. 45. 1985
Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells.. 45. 1985
Pharmacokinetics of vindesine given as an intravenous bolus and 24-hour infusion in humans.. 45. 1985
American cancer society Phase I trial of naturally produced beta-interferon.. 44. 1984
Prolonged binding of a radiolabeled monoclonal antibody (B72.3) used for the in situ radioimmunodetection of human colon carcinoma xenografts.. 44. 1984
Effects of alpha-difluoromethylornithine and methylglyoxal bis(guanylhydrazone) on the growth of experimental renal adenocarcinoma in mice.. 44. 1984
Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by tamoxifen and other triparanol analogues.. 44. 1984
Experimental and clinical activity of mitomycin C and cis-diamminedichloroplatinum in malignant mesothelioma.. 44. 1984
Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by perhexiline maleate.. 44. 1984
Phase I and clinical pharmacology studies of intravenous and oral administration of 4-demethoxydaunorubicin in patients with advanced cancer.. 43. 1983
Enhancement of adriamycin delivery to liver metastatic cells with increased tumoricidal effect using liposomes as drug carriers.. 43. 1983
Phase I evaluation of 2'-fluoro-5-iodo-1-beta-D-arabinofuranosylcytosine in immunosuppressed patients with herpesvirus infection.. 43. 1983
Mitoxantrone in patients with acute leukemia in relapse.. 43. 1983
Shedding and immunoregulatory activity of YAC-1 lymphoma cell gangliosides.. 43. 1983
Multivariate analysis of prognostic variables in patients with metastatic testicular cancer.. 43. 1983
Thermal survival characteristics of cell subpopulations isolated from a heterogeneous human colon tumor.. 43. 1983
Lymphoma cell-mediated degradation of sulfated proteoglycans in the subendothelial extracellular matrix: relationship to tumor cell metastasis.. 43. 1983
Kinetic and catabolic considerations of monoclonal antibody targeting in erythroleukemic mice.. 43. 1983
Glucose metabolism and the percentage of glucose derived from alanine: response to exogenous glucose infusion in tumor-bearing and non-tumor-bearing rats.. 42. 1982
Phase I clinical trial and pharmacokinetics of 4'-carboxyphthalato(1,2-diaminocyclohexane)platinum(II).. 42. 1982
Differential responses to x-irradiation of subpopulations of two heterogeneous human carcinomas in vitro.. 42. 1982
HLA antigens in patients with germ cell cancers of the testis.. 42. 1982
Phase II study of 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992) in children with acute leukemia and lymphoma.. 42. 1982
Characterization of bladder papilloma by two-parameter DNA-RNA flow cytometry.. 42. 1982
Controlled clinical trials of nutritional intervention as an adjunct to chemotherapy, with a comment on nutrition and drug resistance.. 42. 1982
Leukemic cell targeting and therapy by monoclonal antibody in a mouse model system.. 42. 1982
Surface marker identification of small cleaved follicular center cell lymphomas with a highly favorable prognosis.. 42. 1982
Tumoricidal potential of nutritional manipulations.. 42. 1982
Eastern Cooperative Oncology Group study of the cytochemistry of adult acute myeloid leukemia by correlation of subtypes with response and survival.. 41. 1981
Abnormal 24-hr mean plasma concentrations of dehydroisoandrosterone and dehydroisoandrosterone sulfate in women with primary operable breast cancer.. 41. 1981
Phase I and pharmacological studies of pentamethylmelamine administered by 24-hour intravenous infusion.. 41. 1981
High-volume intraperitoneal chemotherapy with methotrexate in patients with cancer.. 41. 1981
Direct cloning of human parathyroid hyperplasia cells in soft-agar culture.. 40. 1980
Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally.. 40. 1980
Detection of breast tumor antigen-sensitive circulating T-lymphocytes by antigen-stimulated active rosette formation.. 39. 1979
Specific cellular immune responses in patients with malignant gliomas.. 39. 1979
DNA damage in the intracerebral rat gliosarcoma 9L treated with 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.. 37. 1977
DNA damage and repair in L1210 cells exposed to 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.. 37. 1977
Uncomplicated starvation versus cancer cachexia.. 37. 1977
Decreased ability of blood leukocytes from patients with tumors of the urinary bladder to act as stimulator cells in mixed leukocyte culture.. 36. 1976
Elevation of dihydrofolate reductase, thymidylate synthetase, and thymidine kinase in cultured mammalian cells after exposure to folate antagonists.. 36. 1976
Pathological review of breast lesions analyzed for estrogen receptor protein.. 35. 1975
Inhibition and recovery of DNA synthesis in host tissues and sensitive and resistant B16 melanoma after 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea, a predictor of therapeutic efficacy.. 35. 1975
Daunorubicin in the therapy of acute granulocytic leukemia.. 33. 1973
Evaluation of aniline mustard in patients with multiple myeloma.. 33. 1973
Stimulatory effects of inosine and deoxyinosine on the incorporation of uracil-2-14-C, 5-fluorouracil-2-14-C, and 5-bromouracil-2-14-C into nucleic acids by Ehrlich ascites tumor cells in vitro.. 29. 1969
On the mechanism of the nucleoside stimulation of amino acid incorporation into protein of Ehrlich ascites tumor cells in vitro.. 27. 1967
Evaluation of tryptophan mustard (NSC-62403) in patients with plasmacytic myeloma.. 27. 1967
The need for axillary lymph node dissection in T1/T2 breast cancer surgery--reply to counterpoint.. 73. 2013
Epigenetic Cooperativity as a Therapeutic Vulnerability in Cancer. 2023
Imaging Early Response to Checkpoint Inhibition. 2021
Leveraging Systematic Functional Analysis to Benchmark an In Silico Framework Distinguishes Driver from Passenger MEK Mutants in Cancer. 2020
Differential Contributions of Pre- and Post-EMT Tumor Cells in Breast Cancer Metastasis. 2019
Correspondence re: L. Yang et al., Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated Smac peptide. Cancer Res., 63: 831-837, 2003. 2003
TbetaR-I(6A) polymorphism is not a tumor susceptibility allele in Macedonian colorectal cancer patients. Correspondence re: B. Pasche et al. Type I TbetaR-I(6A) Is a Candidate Tumor Susceptibility Allele. Cancer Res., 58: 2727-2732, 1998. 2001
PI3King the Environment for Growth: PI3K Activation Drives Transcriptome Changes That Support Oncogenic Growth.. 82. 2022
Beyond T Cells: IgA Incites Immune Recognition in Endometrial Cancer.. 82. 2022
It is not always necessary to do axillary dissection for T1 and T2 breast cancer--point. 2013
Androgen receptor on the move: boarding the microtubule expressway to the nucleus. 2012
Preparing the "soil": the premetastatic niche. 2006
Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium. 2004
Histone H1 Mutations in Lymphoma: A Link(er) between Chromatin Organization, Developmental Reprogramming, and Cancer. 2021
Brain Metastasis Cell Lines Panel: A Public Resource of Organotropic Cell Lines. 2020
A Tribute to John Mendelsohn: A Pioneer in Targeted Cancer Therapy. 2019
Detection of NTRK Fusions: Merits and Limitations of Current Diagnostic Platforms. 2019
Diffusion-weighted imaging in cancer: physical foundations and applications of restriction spectrum imaging. 2014
Patient-derived tumor xenografts: transforming clinical samples into mouse models. 2013
Microenvironmental regulation of epithelial-mesenchymal transitions in cancer. 2012
Emerging paradigms in cancer genetics: some important findings from high-density single nucleotide polymorphism array studies. 2009
ATP depletion + pyrimidine depletion can markedly enhance cancer therapy: fresh insight for a new approach. 2000
Prevention of cancer in the next millennium: Report of the Chemoprevention Working Group to the American Association for Cancer Research. 1999
Improving the balance between treatment and diagnosis: a role for radioimmunodetection. 1995
Antigen selection in human lymphomagenesis. 1992
Clinical radioimmunodetection, 1978-1988: overview and suggestions for standardization of clinical trials. 1990

VIVO Weill Cornell Medical College

Cancer research Journal

Overview

publication venue for

Identity

ISO Abbreviation

Linking ISSN

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)